Saturday, May 8, 2021

TOPICS

Home Tags Pablo J. Cagnoni

Tag: Pablo J. Cagnoni

Rubius Therapeutics reports $40.9M loss in Q3

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter. The clinical-stage biopharmaceutical...
RUBIUS THERAPEUTICS spent $163.5 million in 2019. The company does not yet generate revenue.

Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and...

PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018. Loss per diluted share...
RUBIUS THERAPEUTICS reported a loss of $39.4 million in the second quarter of 2019. The company has yet to record revenue..4 million in the second quarter of 2019, The company is yet to have revenue.

Rubius reports $39.4M loss in Q2, heralds progress

PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...
RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.

Rubius Therapeutics reports $32.6M loss in Q1

SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share,...
RUBIUS THERAPEUTICS reported a $26.4 million loss for the third quarter. The company does not yet generate revenue.

Rubius reports $26.4M loss for Q3

PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an...

Rubius Therapeutics enters agreement to buy former Alexion site in Smithfield

SMITHFIELD – Rubius Therapeutics Inc., the Cambridge, Mass.-based company recently approved by the R.I. Commerce Corp. for up to $9 million in incentives to...

Stay up to date with PBN's Morning Call & Daily Edition newsletters.

- Featured Event -

Latest News

Sign-up to get the

PBN Daily Edition

A collection of all the published news of the last 24 hours, as well as selected features from PBN’s weekly print edition.

By submitting the form you agree to PBN's Privacy Policy and Terms of Use.

Subscribe with Providence Business News to keep reading.

We’re glad you are enjoying PBN.